Lung Therapeutics, Inc.

Lung Therapeutics, Inc. Lung Therapeutics, Inc. is a pharmaceutical company targeting niche, orphan drug indications for lun

is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs and fibrinous scar tissue in the pleural cavity blocks fluid drainage. Our fir

st product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. By clearing the fibrinous buildup pharmaceutically, the clinical pathway for these patients is significantly improved, enabling simple draining of pleural fluid without surgery. Our longer-term efforts will target improvement of clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis and other disease conditions.

Happy World Health Day!!
04/07/2023

Happy World Health Day!!

03/24/2023
It's great to have new team members. Welcome Sydney Kruger to the Lung team!
02/28/2023

It's great to have new team members. Welcome Sydney Kruger to the Lung team!

World Pneumonia Day - Let's raise awareness, promote interventions and generate action.
11/12/2022

World Pneumonia Day - Let's raise awareness, promote interventions and generate action.

09/14/2022

Please join us for the second annual Interstitial Lung Disease (ILD) Day! For more information and resources about ILD, visit www.ILDDay.org.

September is Pulmonary Fibrosis Awareness Month
09/06/2022

September is Pulmonary Fibrosis Awareness Month

One week away until the 6th Annual IPF Summit in Boston. Brian Windsor will be speaking on day 2 of the summit (8/31):• ...
08/22/2022

One week away until the 6th Annual IPF Summit in Boston. Brian Windsor will be speaking on day 2 of the summit (8/31):
• 9:45 am Divulging the Clinical Development of LTI-03 in IPF
Synopsis
- Assessing the "dual threat" of LTI-03: inhibition of the profibrotic process and lung regenerative effects
- Uncovering how biomarkers could be sues to reveal these properties

• 11:00 am Panel Discussion: Reflecting on the Progress & Lessons Learned in IPF Clinical Drug Development - Where Will the IPF Road lead us Next?
Panel Discussion group includes the following:
- Peter Smith, Vice President - Product Development, United Therapeutics
- Brian Windsor, Chief Executive Officer, Lung Therapeutics
- Eric White, Senior Clinical Program Lead, Boehringer Ingelheim

Lung Therapeutics honors those suffering with lung cancer.
08/01/2022

Lung Therapeutics honors those suffering with lung cancer.

The Lung Therapeutics Team is looking forward to . We hope to see you there!
05/13/2022

The Lung Therapeutics Team is looking forward to . We hope to see you there!

starts today! We're excited to safely reconnect in San Francisco after 2 years!

Address

3801 S. Capital Of Texas Highway, Suite 330
Austin, TX
78704

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+17378021989

Website

Alerts

Be the first to know and let us send you an email when Lung Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category